The Scott Hamilton CARES Foundation, established as a national identity in 2014, is dedicated to changing the future of cancer by funding advanced, innovative research that treats the cancer while sparing the patient.
Cancer knows no boundaries of age, gender or race and as our population ages the number of survivors living with the after effects of cancer treatment rises. Cancer care over the past 45 years has advanced in every area and more people are surviving than ever before. Breakthroughs in our understanding of cancer is driving new treatments with less devastating side effects from highly toxic cancer treatments.
We will remain flexible in our thinking and constantly on the lookout for new and innovative ideas, so we can stay abreast of emerging trends in research with the potential to increase the impact of our funding. Scott Hamilton CARES Foundation supports research that accelerates the advancement of less toxic treatments for isolated cancers and tumors with precision proton beam therapy and prevention of the spread of cancer with targeted immunotherapy drugs.
You may ask why our focus is on these two forms of cancer treatments?
Immunotherapy targeted drugs
While immunotherapy prescribed medications are fairly new, thanks to research funding and clinical trials immunotherapy drugs are already becoming the new standard of cancer treatment. Immunotherapy continues to represent the greatest hope for those diagnosed with cancer and our investments will continue to expand in this area. These drugs are targeted to the unique genetics of each tumor and individual. The targeted drugs block or switch off and/or attach to the cancer cells and leave the healthy cells untouched, unlike traditional chemotherapy. This results in better cancer control, prevention and ultimately, a better quality of life.
Precision Targeted Beam Proton Therapy
Technology advancements from when radiologists developed treatment plans on x-ray films are now intricate computerized proton targeted treatments directed at the cancer tumor. The advancements allow radiologists to tailor the radiation beam down to the size of a pencil lead to minimize the risk of damage to healthy tissue, improve survival, and minimize potential serious side effects of traditional radiation treatment.
The v foundation and CARES Partnership funding pediatric immuno-oncology research
"We at the V Foundation are so grateful to the Scott Hamilton CARES Foundation for their tireless efforts to raise funds and awareness for cutting-edge research for precision medicine," said Susan Braun, CEO of the V Foundation for Cancer Research. The Scott Hamilton CARES Foundation in partnership with the V Foundation is providing funding for a research grant for an additional year under the success of Robert Wechsler-Reya Ph.D. at Sanford Burnham Prebys Medical Discovery Institute in California.
Dr. Wechsler-Rey's research is dedicated to pediatric immune-oncology focusing on immunotherapy for medulloblastoma, the most common malignant brain tumor in children. The continued funding of this research endeavor is beneficial to our mission. Since the first research grant was funded in 2017, Dr. Wechsler-Ray and his research team have begun to extend their findings to tumors other than medulloblastoma to include brainstem glioma, which is an aggressive brain tumor with nearly 100% mortality. Based on research results, they have found favorable outcomes that move their findings towards clinic and patient care. The results indicate how immunotherapy is enhanced in patients with brain tumors.
Scott Hamilton CARES Foundation is committed to a future where research funding is accessible to cancer research institutions across the country. Through our National Charity of Choice Program, as part of our Sk8 to Elimin8 Cancer Program, we have been able to increase awareness of cancer and local resources in various cities in which we partner and raise funds. Since launching our Charity of Choice Program in 2017, CARES has funded 15 initiatives nationwide.